동물 모델 시장 규모, 점유율 및 동향 분석 보고서 : 동물 유형별, 용도별, 최종 용도별, 지역별 및 부문 예측(2026-2033년)

Animal Model Market Summary

The global animal model market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 2.8 billion in 2026 to USD 5.4 billion by 2033, at a CAGR of 9.6% from 2026 to 2033. North America held the largest revenue share of 50.6% in 2025.

The growth of the animal model industry is driven by rising demand for preclinical research, drug discovery applications, and translational biomedical studies, as well as increasing investments in biopharmaceutical R&D, advanced genetic engineering techniques, and the expanding use in personalized medicine development globally across major regions.

Global Animal Model Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal model market report based on animal type, application, end-use, and region:

• Animal Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Mice
• Rat
• Guinea Pigs
• Rabbits
• Hamsters
• Others
• Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Cancer
• Immunological Disease
• Infectious Disease
• Others
• End-use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic Research Institute
• Contract Research Organization
• Regional Outlook (Revenue, USD Million/Billion, 2021- 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Animal Type Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
  • 1.4.3. Objective 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Case Study Insights
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. PESTEL Analysis

Chapter 4. Animal Type Business Analysis

• 4.1. Animal Model Market: Animal Type Movement Analysis
• 4.2. Mice
  • 4.2.1. Mice Market, 2021 - 2033 (USD Million/Billion)
• 4.3. Rat
  • 4.3.1. Rat Market, 2021 - 2033 (USD Million/Billion)
• 4.4. Guinea Pig
  • 4.4.1. Guinea Pig Market, 2021 - 2033 (USD Million/Billion)
• 4.5. Rabbits
  • 4.5.1. Rabbits Market, 2021 - 2033 (USD Million/Billion)
• 4.6. Hamsters
  • 4.6.1. Hamsters Market, 2021 - 2033 (USD Million/Billion)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Application Business Analysis

• 5.1. Animal Model Market: Application Movement Analysis
• 5.2. Cancer
  • 5.2.1. Cancer Market, 2021 - 2033 (USD Million/Billion)
• 5.3. Immunological Disease
  • 5.3.1. Immunological Disease Market, 2021 - 2033 (USD Million/Billion)
• 5.4. Infectious Disease
  • 5.4.1. Infectious Disease Market, 2021 - 2033 (USD Million/Billion)
• 5.5. Others
  • 5.5.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 6. End Use Business Analysis

• 6.1. Animal Model Market: End Use Movement Analysis
• 6.2. Pharmaceutical & Biotechnology Companies
  • 6.2.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million/Billion)
• 6.3. Academic Research Institute
  • 6.3.1. Academic Research Institute Market, 2021 - 2033 (USD Million/Billion)
• 6.4. Contract Research Organization
  • 6.4.1. Contract Research Organization Market, 2021 - 2033 (USD Million/Billion)

Chapter 7. Regional Business Analysis

• 7.1. Animal Model Market Share By Region, 2025 & 2033
• 7.2. North America
  • 7.2.1. North America Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. U.S. Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Canada Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Competitive Scenario
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Mexico Animal Model Market, 2021 - 2033 (USD Million/Billion)
• 7.3. Europe
  • 7.3.1. Europe Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. UK Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Germany Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. France Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Competitive Scenario
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Italy Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Competitive Scenario
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Spain Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Competitive Scenario
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Denmark Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Competitive Scenario
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Sweden Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Competitive Scenario
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Norway Animal Model Market, 2021 - 2033 (USD Million/Billion)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Japan Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. China Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. India Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.5. Australia
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Australia Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.6. Thailand
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Thailand Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.4.7. South Korea
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. South Korea Animal Model Market, 2021 - 2033 (USD Million/Billion)
• 7.5. Latin America
  • 7.5.1. Latin America Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Brazil Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Argentina Animal Model Market, 2021 - 2033 (USD Million/Billion)
• 7.6. MEA
  • 7.6.1. MEA Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. South Africa Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Saudi Arabia Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. UAE Animal Model Market, 2021 - 2033 (USD Million/Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Kuwait Animal Model Market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share/Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Charles River Laboratories
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. The Jackson Laboratory
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. genOway
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Taconic Biosciences, Inc
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Janvier Labs
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. BioModels, LLC.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Crown Bioscience
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Inotiv
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. BIOCYTOGEN
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Hooke Laboratories
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives